Multiple Sclerosis D009103

Description

An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)   MeSH

Subtype Terms (2)

Multiple Sclerosis, Chronic Progressive
61 drugs (31 approved, 30 experimental)

Multiple Sclerosis, Relapsing-Remitting
155 drugs (85 approved, 70 experimental)


Phase 2 Indicated Drugs (96)


Organization Involved with Phase 4 Indications (97)

Organization Involved with Phase 3 Indications (211)

Hampton Roads Neurology

Haugesund Hospital

Helse Forde

Hoosier Cancer Research Network

Hopital Maison Blanche

Hospital of Central Denmark Region, Viborg, Denmark

Hospital of South West Jutland

Humboldt University

ICM - Brain & Spine Institute

Impax Laboratories

Indiana University

Indivior Inc.

Institut fur Klinische Forschung, Germany

Iowa Health Des Moines

Ipsen

Island Neurological Associates, PC

Istituto Don Carlo Gnocchi Divisione Neurologica Riabilitativa. Via Capecelatro 66 20148 Milano

Istituto Superiore di Sanità

Italian Multiple Sclerosis Foundation

Josephson Wallack Munshower Neurology, PC

Karolinska Institute

Klinikum Luedenscheid

Kocaeli University

Lillehammer Hospital

Loma Linda University

London Health Sciences Centre

Lundbeck

Mapi Pharma Ltd.

Mayo Clinic

Mazandaran University of Medical Sciences

MedDay Pharmaceuticals

Melbourne Health

Mercy Multiple Sclerosis Center of Oklahoma Mercy Neuroscience Institute

Metrolina Medical Research

Molde University College

MonitorCRO

Multiple Sclerosis Society of Canada

National Center for Research Resources (NCRR)

National Eye Institute (NEI)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institutes of Health (NIH)

Negroski, Stein, Sutherland and Hanes Neurology

NeuroCure Clinical Research Center

Neurologique Foundation, Inc.

Neurology Center of New England P.C.

Neurology Specialists, Inc.

Nordland Hospital

North Central Neurology Associates, PC

Northwestern University

Norwegian University of Science and Technology

Nuron Biotech

Ohio State University

Oregon Health and Science University

Organization Involved with Phase 2 Indications (168)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.